BioNTech is a German biopharmaceutical company with one commercial product — Comirnaty, the mRNA COVID-19 vaccine co-developed with Pfizer — and a late-stage oncology pipeline it is building toward commercial launch. Comirnaty is updated annually for the current SARS-CoV-2 strain and sold globally. BioNTech holds direct marketing rights in Germany and Türkiye; Pfizer commercializes the vaccine everywhere else (except China, where Fosun Pharma distributes), with gross profits split 50/50. COVID revenue is highly seasonal, concentrated in fall and winter. BioNTech's strategic priority is oncology, where it has no approved products yet but two lead programs. The first is pumitamig, a bispecific antibody targeting both PD-L1 and VEGF-A, in Phase 3 trials for lung and breast cancers, co-developed and co-commercialized 50/50 with Bristol Myers Squibb. The second is a pair of mRNA cancer vaccine platforms — a personalized neoantigen vaccine (partnered with Genentech) and an off-the-shelf tumor antigen vaccine — both targeting early-stage cancer settings. BioNTech also has a pipeline of antibody-drug conjugates, including trastuzumab pamirtecan, a HER2-targeting ADC with a BLA submission planned for 2026 in endometrial cancer. Near-term oncology revenues come primarily from the BMS collaboration, which includes $3.5B in upfront and committed payments recognized over time. BioNTech's long-term goal is to transition from a single-product vaccine company to a multi-product oncology business.